Clinical trials: Semaglutide, completed
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 4 (NCT03548987)
- Testing
- Semaglutide
- Where
- 72 sites in United States, Denmark and 8 more
- Volunteers
- 902 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 3 (NCT03611582)
- Testing
- Semaglutide
- Where
- 41 sites in United States
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Alzheimers Disease
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease.
- Trial name
- NCT05891496
- Testing
- Semaglutide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
In this study, participants will receive semaglutide and NNC0480-0389 together at the same time. Semaglutide is a medicine that can already be prescribed, whereas NNC0480-0389 is a new potential medicine.
- Trial name
- NCT05046873
- Testing
- Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Alcohol-related Liver Disease
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease.
- Trial name
- NCT06409130
- Testing
- NNC0194-0499, Semaglutide, Cagrilintide + semaglutide
- Where
- 102 sites in United States, Australia and 12 more
- Volunteers
- 270 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes
Semaglutide 2.4 mg in Patients With Poor Weight-loss
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery.
- Conditions
- Obesity, Diabetes, Metabolic Syndrome
- Trial name
- BARI-STEP (NCT05073835)
- Testing
- Semaglutide 3 mg
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- University College, London
Obesity
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in…
- Trial name
- STEP UP (NCT05646706)
- Testing
- Semaglutide
- Where
- 107 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,407 people
- Sponsor
- Novo Nordisk A/S
Gastric Retention
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying.
- Trial name
- RESIDUAL (NCT06500143)
- Testing
- Gastric ultrasound
- Where
- Canada
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Stroke, Stroke, Acute
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
Endovascular thrombectomy (EVT) is a highly effective therapy for acute ischemic stroke with large vessel occlusion (LVO). EVT was proven efficacious in selected patients with symptoms onset or last-known-well time of up to 24…
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases
- Trial name
- GALLOP (NCT05920889)
- Testing
- Semaglutide
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 140 people
- Sponsor
- Chinese University of Hong Kong
Type 2 Diabetes, Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects.
- Trial name
- NCT06184568
- Testing
- IBI362, Semaglutide
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity, Overweight
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own.
- Trial name
- NCT03600480
- Testing
- NNC0174-0833, Semaglutide
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Novo Nordisk A/S
Obesity, Obese
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
- Conditions
- Obesity, Obese, Overweight or Obesity
- Trial name
- NCT05616013
- Testing
- Bimagrumab, Semaglutide
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 507 people
- Sponsor
- Eli Lilly and Company
Idiopathic Intracranial Hypertension, Intracranial Pressure
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide…
- Conditions
- Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome
- Trial name
- IIH:DUAL (NCT06027567)
- Testing
- Semaglutide, Very Low Calorie Diet, Dietician counselling
- Where
- 2 sites in Denmark
- Volunteers
- 38 people
- Sponsor
- Rigmor Højland Jensen
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide (NNC0113-0217) in subjects with mild…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02016911
- Testing
- semaglutide
- Where
- 6 sites in Czechia, Poland and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE CANADA (NCT03457012)
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 462 people
- Sponsor
- Novo Nordisk A/S
Obesity
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study.
- Trial name
- NCT04998136
- Testing
- Semaglutide 2.4 mg
- Where
- 16 sites in South Korea, Thailand
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight.
- Trial name
- OASIS 1 (NCT05035095)
- Testing
- Oral semaglutide
- Where
- 56 sites in United States, Canada and 7 more
- Volunteers
- 667 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease, Type 2 Diabetes
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Obesity
- Trial name
- NCT06131372
- Testing
- Cagrilintide, Semaglutide
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 626 people
- Sponsor
- Novo Nordisk A/S
Major Depressive Disorder
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).
- Trial name
- NCT04466345
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- University Health Network, Toronto